Skip to main content
Erschienen in:

21.04.2020 | COVID-19 | Original Article - Neurosurgery general Zur Zeit gratis

The impact of COVID-19 on neurosurgeons and the strategy for triaging non-emergent operations: a global neurosurgery study

verfasst von: Walter C. Jean, Natasha T. Ironside, Kenneth D. Sack, Daniel R. Felbaum, Hasan R. Syed

Erschienen in: Acta Neurochirurgica | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Object

The COVID-19 pandemic has disrupted all aspects of society globally. As healthcare resources had to be preserved for infected patients, and the risk of in-hospital procedures escalated for uninfected patients and staff, neurosurgeons around the world have had to postpone non-emergent procedures. Under these unprecedented conditions, the decision to defer cases became increasingly difficult as COVID-19 cases skyrocketed.

Methods

Data was collected by self-reporting surveys during two discrete periods: the principal survey accrued responses during 2 weeks at the peak of the global pandemic, and the supplemental survey accrued responses after that to detect changes in opinions and circumstances. Nine hypothetical surgical scenarios were used to query neurosurgeons’ opinion on the risk of postponement and the urgency to re-schedule the procedures. An acuity index was generated for each scenario, and this was used to rank the nine cases.

Results

There were 494 respondents to the principal survey from 60 countries. 258 (52.5%) reported that all elective cases and clinics have been shut down by their main hospital. A total of 226 respondents (46.1%) reported that their operative volume had dropped more than 50%. For the countries most affected by COVID-19, this proportion was 54.7%. There was a high degree of agreement among our respondents that fast-evolving neuro-oncological cases are non-emergent cases that nonetheless have the highest risk in postponement, and selected vascular cases may have high acuity as well.

Conclusion

We report on the impact of COVID-19 on neurosurgeons around the world. From their ranking of the nine case scenarios, we deduced a strategic scheme that can serve as a guideline to triage non-emergent neurosurgical procedures during the pandemic. With it, hopefully, neurosurgeons can continue to serve their patients without endangering them either neurologically or risking their exposure to the deadly virus.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
13.
Zurück zum Zitat Chang DX, Huiwen RA, Sharma L, Dela Cruz CS (2020) Protecting health-care workers from subclinical coronavirus infection. Lancet Respir Med Mar 8(3):e13CrossRef Chang DX, Huiwen RA, Sharma L, Dela Cruz CS (2020) Protecting health-care workers from subclinical coronavirus infection. Lancet Respir Med Mar 8(3):e13CrossRef
Metadaten
Titel
The impact of COVID-19 on neurosurgeons and the strategy for triaging non-emergent operations: a global neurosurgery study
verfasst von
Walter C. Jean
Natasha T. Ironside
Kenneth D. Sack
Daniel R. Felbaum
Hasan R. Syed
Publikationsdatum
21.04.2020
Verlag
Springer Vienna
Schlagwort
COVID-19
Erschienen in
Acta Neurochirurgica / Ausgabe 6/2020
Print ISSN: 0001-6268
Elektronische ISSN: 0942-0940
DOI
https://doi.org/10.1007/s00701-020-04342-5

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Neurologie

Belastungs-Malaise erschwert Reha bei Long-COVID

Um Menschen mit Langzeitfolgen von COVID-19 wirksam zu rehabilitieren, ist eine etwaige Post-Exertional Malaise unbedingt mitzuberücksichtigen, und das Trainingsprogramm entsprechend anzupassen.

Neuartige Antikörpertherapie bremst MS über zwei Jahre hinweg

Eine Therapie mit dem C40-Ligand-Blocker Frexalimab kann MS-Schübe und neue MRT-Läsionen über zwei Jahre hinweg verhindern. Dafür spricht die Auswertung einer offen fortgeführten Phase-2-Studie.

Therapiestopp bei älteren MS-Kranken kann sich lohnen

Eine Analyse aus Kanada bestätigt: Setzen ältere MS-Kranke die Behandlung mit Basistherapeutika ab, müssen sie kaum mit neuen Schüben und MRT-Auffälligkeiten rechnen.

Positive Phase IIb-Studie zu spezifischer CAR-T-Zell-Therapie bei Myasthenia gravis

Eine auf das B-Zell-Reifungsantigen gerichtete mRNA-basierte CAR-T-Zell-Therapie wurde jetzt in einer ersten Phase IIb-Studie zur Behandlung der generalisierten Myasthenia gravis mit Placebo verglichen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.